These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18024447)

  • 21. Evidence requirements for innovative imaging devices: from concept to adoption.
    Frank RA; Rucker DW; Ferguson MA; Sweeney TJ
    J Am Coll Radiol; 2011 Feb; 8(2):124-31. PubMed ID: 21292189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory and reimbursement innovation.
    Lindor RA; Allocco SJ; Cheatham L; Cortese DA; Hall RF; Mangold WJ; Pizziconi V; Poste G; Quinn B; Roth M; Saks MJ; Wassman ER; Woosley RL; Marchant GE
    Sci Transl Med; 2013 Mar; 5(176):176cm3. PubMed ID: 23486776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear medicine comes of age: its present and future roles in diagnosis.
    McAfee JG; Kopecky RT; Frymoyer PA
    Radiology; 1990 Mar; 174(3 Pt 1):609-20. PubMed ID: 2406775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulating molecular diagnostic assays: developing a new regulatory structure for a new technology.
    Gibbs JN
    Expert Rev Mol Diagn; 2011 May; 11(4):367-81. PubMed ID: 21545255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis in the assessment of diagnostic imaging technologies.
    Gazelle GS; McMahon PM; Siebert U; Beinfeld MT
    Radiology; 2005 May; 235(2):361-70. PubMed ID: 15858079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of regulation and payment innovations on acquisition of new imaging technologies.
    Steinberg EP
    Radiol Clin North Am; 1985 Sep; 23(3):381-9. PubMed ID: 3933046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noninvasive structural, functional, and molecular imaging in drug development.
    Rudin M
    Curr Opin Chem Biol; 2009 Jun; 13(3):360-71. PubMed ID: 19447067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is hybridic positron emission tomography/computerized tomography the only option? The future of nuclear medicine and molecular imaging.
    Grammaticos P; Zerva C; Asteriadis I; Trontzos C; Hatziioannou K
    Hell J Nucl Med; 2007; 10(2):74-6. PubMed ID: 17684579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiology reimbursement.
    Kidd KL
    Appl Radiol; 1989 May; 18(5):16-21. PubMed ID: 10294838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Availability of molecular imaging and "personalized medicine.".
    Baranowska-Kortylewicz J; Henriksen JB
    J Nucl Med; 2009 Jan; 50(1):16N. PubMed ID: 19139183
    [No Abstract]   [Full Text] [Related]  

  • 32. Multimodality cardiovascular molecular imaging, part I.
    Sinusas AJ; Bengel F; Nahrendorf M; Epstein FH; Wu JC; Villanueva FS; Fayad ZA; Gropler RJ
    Circ Cardiovasc Imaging; 2008 Nov; 1(3):244-56. PubMed ID: 19808549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical applications of molecular imaging methods for patients with ischemic stroke].
    Yamauchi H; Fukuyama H
    Nihon Rinsho; 2007 Feb; 65(2):315-9. PubMed ID: 17302277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of MR imaging on nationwide health care costs and comparison with other imaging procedures.
    Levin DC; Spettell CM; Rao VM; Sunshine J; Bansal S; Busheé GR
    AJR Am J Roentgenol; 1998 Mar; 170(3):557-60. PubMed ID: 9490930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What's next after 50 years of psychiatric drug development: an FDA perspective.
    Laughren TP
    J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness and future implications for cardiovascular imaging.
    Shaw LJ
    Can J Cardiol; 2013 Mar; 29(3):350-7. PubMed ID: 23332968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary markers in the detection of bladder cancer: what's new?
    Nielsen ME; Schaeffer EM; Veltri RW; Schoenberg MP; Getzenberg RH
    Curr Opin Urol; 2006 Sep; 16(5):350-5. PubMed ID: 16905981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Federal regulations and reimbursement for PET.
    Keppler JS
    J Nucl Med Technol; 2001 Dec; 29(4):173-9; quiz 180-2. PubMed ID: 11756528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overhauling the reimbursement system for molecular diagnostics.
    Malik NN
    Nat Biotechnol; 2011 May; 29(5):390-1. PubMed ID: 21552233
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.